As of April 12, 2018, 12,781,195 shares of the registrant's common stock were issued and outstanding.
ARTELO BIOSCIENCES, INC. (the "Company") is a Nevada corporation incorporated on May 2, 2011. It is based in San Diego County, California. The accounting and reporting policies of the Company conform to accounting principles generally accepted in the United States of America, and the Company's fiscal year end is August 31.
Effective on February 10, 2017, the Company changed its name from "KNIGHT KNOX DEVELOPMENT CORP.," to "REACTIVE MEDICAL INC." On April 14, 2017, the Company changed its name from "REACTIVE MEDICAL INC." to "ARTELO BIOSCIENCES, INC".
In May 2017, the Company registered fully owned subsidiaries in England and Wales, Trinity Reliant Ventures Limited, and Trinity Research & Development Limited. Operations in the subsidiary have been consolidated in the financial statements.
The Company intends to license, develop and commercialize novel therapeutic treatments targeting the endocannabinoid system. To date, the Company's activities have primarily been limited to its formation, business development activities, sponsored research, and the raising of equity capital.
The Company prepares its financial statements in accordance with rules and regulations of the Securities and Exchange Commission ("SEC") and accounting principles generally accepted ("GAAP") in the United States of America. The accompanying interim financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information in accordance with Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the Company's opinion, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the six months ended February 28, 2018 are not necessarily indicative of the results for the full year. While management of the Company believes that the disclosures presented herein are adequate and not misleading, these interim financial statements should be read in conjunction with the audited financial statements and the footnotes thereto for the year ended August 31, 2017 contained in the Company's Form 10-K filed on November 29, 2017.
The financial statements have been prepared on a consolidated basis, with the Company's fully owned subsidiary Trinity Reliant Ventures Limited. No intercompany balances or transactions exist during the period ended February 28, 2018.
The Company's financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not established an ongoing source of revenues sufficient to cover its operating cost, and requires additional capital to commence its operating plan. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. If the Company is unable to obtain adequate capital, it could be forced to cease operations. These factors raise substantial doubt about its ability to continue as a going concern.
The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. During the six months ended February 28, 2018, the Company has a net loss of $905,411. As at February 28, 2018, the Company had an accumulated deficit of $1,200,500 and has earned no revenues. The Company intends to fund operations through equity financing arrangements, which may be insufficient to fund its capital expenditures, working capital and other cash requirements for future periods.
During the six months ended February 28, 2018, the president of the Company incurred $740 of expenses on behalf of the Company. The amount owing to the related party as of February 28, 2018 and August 31, 2017 is $1,602 and $862, respectively. The amounts are non-interest bearing and have no terms of repayment.
During the six months ended February 28, 2018, the former President, and current Senior Vice President, European Operations, who is a major shareholder paid rent expense on behalf of the Company, and paid for expenses on behalf of the company for a total of $15,843. The amount of $15,843 was repaid during the six months ended February 28, 2018. The amount owing to the related party as of February 28, 2018 and August 31, 2017 is $0 and $0, respectively. The amounts are non-interest bearing, and have no terms of repayment.
The Company has an employment contract with a key employee, Mr. Gregory Gorgas, who is an officer of the Company. Effective January 26, 2018 the annual base salary is $125,000. As of February 28, 2018, $12,340 was paid in salary and $25,934 was paid reimbursement for payments made by him for his health benefits, retroactive to the beginning of his employment. The amounts and terms of the above transactions may not necessarily be indicative of the amounts and terms that would have been incurred had comparable transactions been entered into with independent third parties.
On September 20, 2017, the Company appointed 2 additional Directors. Each Director was granted a restricted stock award (the "RSA") for 100,000 shares of the Company's common stock, vesting annually over a four year period, in each case subject to such director's continued service to the Company. During the six months ended February 28, 2018, the company recorded $30,001 of stock compensation expense for all five members of the Company's Board of Directors.
On January 26, 2018, the Company received $65,000 from two related parties from shares issuance under subscription agreement. The amounts have been recorded as stock common stock issued, and will be settled with shares of the Company subsequent to quarter end. The amounts of $65,000 with related parties is for the issuance of 99,999 common shares, purchase price of $0.65 and 99,999 warrants with an exercise price of $1.50 per share, and five years expiry date. (See note 5).
The Company has authorized 50,000,000 shares of preferred stock with a par value of $0.001.
During the six months ended February 28, 2018, there were no issuances of preferred stock.
The Company has authorized 150,000,000 common shares with a par value of $0.001 per share. Each common share entitles the holder to one vote, in person or proxy, on any matter on which action of the stockholders of the company is sought.
· The Company received $10,000 that has been recorded as stock issued in relation to a subscription agreement on June 30, 2017, for the issuance of 25,000 common shares.
Per the terms of the subscription agreement, following the closing date until the earlier of (i) the date that the registration is declared effective by the SEC, or (ii) the date the shares become freely tradable, if the Company issues any common stock or common stock equivalent entitling the holder to acquire common stock at a price below $0.40, the Company will be required to issue the subscribers that number of additional unites equal to the difference between the units issued at closing, and the number units the Company would have issued to the subscriber had the offering been completed at this discounted price.
· On January 2, 2018, the Company issued 120,000 shares of its common stock valued at $126,000 to NEOMED for services.
· During the six months ended February 28, 2018, the Company received cash of $582,136 that has been recorded for the issuance of 895,587 common shares at a price of $0.65 per Unit pursuant to a private placement offering conducted by the Company in relation to subscription agreements accepted on January 26, 2018 and March 15, 2018. Each Unit consists of: (i) one (1) share of common stock; and (ii) one (1) Series A Stock Purchase Warrant to purchase one (1) share of common stock at a price of $1.50 per share for a period of 5 years from the issue date.
In relation to the common stock related to subscription agreement dated on June 30, 2017, each individual investor received warrants with the purchase of the stock. For each share purchased, the investor will receive one Series A Common Stock Purchase Warrant to purchase one share of the Company's common stock for a period of five years from the date of the share subscription at June 30, 2017 at a price of $1.00 per share.
In relation to the common stock related to subscription agreement dated on January 26, 2018, each individual investor received warrants with the purchase of the stock. For each share purchased, the investor will receive one Series A Stock Purchase Warrant to purchase one share of the Company's common stock for a period of five years from the date of the share subscription at January 26, 2018 at a price of $1.50 per share.
In relation to the common stock related to subscription agreement dated on March 15, 2018, each individual investor received warrants with the purchase of the stock. For each share purchased, the investor will receive one Series A Stock Purchase Warrant to purchase one share of the Company's common stock for a period of five years from the date of the share subscription at March 15, 2018 at a price of $1.50 per share.
As of February 28, 2018, there are 2,847,889 Series A Common Stock Purchase Warrants outstanding, with a weighted average life remaining of 4.52 years, and average exercise price of $1.16. The warrants have intrinsic value of $741,875 as of February 28, 2018.
Subsequent to February 28, 2018, we entered into Subscription Agreements with 5 individuals, for the purchase and sale of 390,306 units of the Company's equity securities (the "Units") at a price of $0.65 per Unit, pursuant to a private placement offering conducted by the Company for aggregate proceeds of $253,700. Each Unit consists of: (i) one (1) share of common stock; and (ii) one (1) Series A Stock Purchase Warrant to purchase one (1) share of common stock at a price of $1.50 per share for a period of 5 years from the issue date.
On March 16, 2018, the Company received $14,950 for the issuance of 23,000 common shares related to subscription agreement dated on January 26, 2018.
Our financial statements are stated in United States Dollars (US$) and are prepared in accordance with United States Generally Accepted Accounting Principles (GAAP).
As used in this quarterly report, the terms "we", "us", "our" and "our company" mean Artelo Biosciences, Inc., and our wholly owned subsidiaries, Trinity Reliant Ventures Limited, in Ireland, and Trinity Research & Development Limited, in England and Wales unless otherwise indicated.
We were incorporated under the laws of the State of Nevada on May 2, 2011 under the name Knight Knox Development Corp. Our principal address is 888 Prospect Street, Suite 210, La Jolla, California, USA and our European office is located at 29 Fitzwilliam Street, Upper, Dublin 2 Ireland. Our telephone number in North America is 760-943-1689 and our European office number is +353 (1) 443 4604.
From inception to January 2017 our business plan was that of a development stage e-commerce company with the intention of operating a fully functional auction site where customers would register for an account and sell and purchase goods and services. Beginning in April 2017, we changed our business plan and we are now focused on becoming a specialty biopharmaceutical company that intends to license, develop and commercialize novel cannabinoid therapeutic treatments, although we have licensed one provisional patent pertaining to a novel cannabinoid-based drug combination to date, we are not yet developing any such treatments.
On January 19, 2017, a majority of our stockholders and our board of directors approved a name change from Knight Knox Development Corp. to Reactive Medical Inc., to better reflect a change of direction of our business. In addition, the majority stockholder and our board of directors approved an increase to our authorized capital from 75,000,000 shares of common stock, par value $0.001 to 150,000,000 shares of common stock, par value $0.001 and 50,000,000 shares of preferred stock, par value $0.001. The change of name became effective with the OTC Markets at the opening of trading on February 10, 2017 under the symbol "RMED".
On March 30, 2017, Mr. Peter O'Brien resigned his positions as President, Chief Executive Officer, Chief Financial Officer, Secretary and Treasurer of the company and was appointed Senior Vice President of European Operations. On April 3, 2017, Mr. Gregory Gorgas was appointed President, Chief Executive Officer, Chief Financial Officer, Secretary, Treasurer and a member of our board of directors. On that date, the Company entered into an employment contract with Mr. Gorgas, which commits the Company and Mr. Gorgas to specific rights and responsibilities, customary to industry standards. For example, upon fulfilling certain obligations, including raising capital in excess of $5,000,000. Mr. Gorgas will then be paid an annual salary of $250,000 and be eligible for additional compensation in the form of bonus, equity, and benefits, commensurate with industry standards. Per the terms of the employment agreement, that any investment in, or appointment to or continuing service on a board of directors or similar body of, any corporation or entity, must be approved in writing by the Company. The agreement includes non-competition terms. The employment agreement can only be terminated in accordance with the Term of Employment specified in the agreement.
Simultaneously, on April 3, 2017, Mr. Gorgas entered into a stock purchase agreement to purchase 1,760,000 common shares for a purchase price of $1,760.
On April 14, 2017, with the approval of its board of directors and shareholders owning a majority of our company's issued and outstanding shares by written consent in lieu of a meeting, we filed a Certificate of Change with the Secretary of State of Nevada, changing our name to Artelo Biosciences, Inc., effective as of April 28, 2017. The change of name became effective on the OTC Markets on May 2, 2017 under the symbol "ARTL".
On May 2, 2017, we entered into an Exclusive Patent License Agreement with Analog Biosciences, Inc. pursuant to which we obtained an exclusive license to two provisional patent applications, and any patent issued on such patent application, related to a combination product strategy to produce a synergy with cannabidiol which was previously assigned to Analog. We have discontinued development of the two provisional patents licensed from Analog.
On May 2, 2017, we entered into an Indemnification Agreement with its newly elected directors, Ms. Connie Matsui and Mr. Steven Kelly, who were appointed to our Board of Directors on the same date.
Pursuant to the Indemnification Agreement, our company agreed to indemnify Ms. Matsui and Mr. Kelly against all expenses, liability and loss, subject to certain limitations, arising out of their respective duties with our company. The indemnification agreement provides indemnification in addition to the indemnification provided by our company's certificate of incorporation and by-laws and by applicable law. Among other things, the Indemnification Agreement expressly provides indemnification for Ms. Matsui and Mr. Kelly for expenses, liability and loss (actually or reasonably) incurred by each of them in connection with the investigation, defense, settlement or appeal of any proceeding relating to their respective duties with our company. In addition, we have agreed to advance expenses, subject to certain limitations, incurred by Ms. Matsui and Mr. Kelly in connection with the investigation, defense, settlement or appeal of any proceeding to which they are a party or are threatened to be made a party as a result of their respective duties with our company.
On May 4, 2017, we entered into a Note Repayment Agreement with Malibu Investments Limited, pursuant to which our company agreed to repay $31,500, representing all of the principal and accrued interest our company owed Malibu under a Senior Promissory Note dated November 18, 2016, in the principal amount of $30,000. The note was fully repaid during the year ended August 31, 2017.
On July 31, 2017, we entered into an indemnification agreement with Douglas Blayney, MD, who was appointed to our Board of Directors on the same date.
Pursuant to the indemnification agreement, we agreed to indemnify Dr. Blayney against all expenses, liability and loss, subject to certain limitations, arising out of his respective duties with our company. The indemnification agreement provides indemnification in addition to the indemnification provided by our company's certificate of incorporation and by-laws and by applicable law. Among other things, the indemnification agreement expressly provides indemnification for Dr. Blayney for expenses, liability and loss (actually or reasonably incurred by each of them in connection with the investigation, defense, settlement or appeal of any proceeding relating to their respective duties with our company. In addition, we have agreed to advance expenses, subject to certain limitations, incurred by Dr. Blayney in connection with the investigation, defense, settlement or appeal of any proceeding to which he is a party or are threatened to be made a party as a result of his respective duties with our company.
On August 1, 2017, Mr. Peter O'Brien, a member of our Board of Directors and our Senior Vice President – European Operations and our company entered into a stock purchase agreement with ALII Capital LLC, a Washington limited liability corporation pursuant to which Mr. O'Brien sold 300,000 shares of our stock owned by him for $300. Pursuant to the terms of the agreement, we granted ALII Capital demand registration rights for the shares purchased.
On September 20, 2017, we entered into indemnification agreements with each of Ms. Georgia Erbez and R. Martin Emanuele, PhD, who were appointed to our Board of Directors on the same date.
Pursuant to the indemnification agreements, we agreed to indemnify Ms. Erbez and Dr. Emanuele against all expenses, liability and loss, subject to certain limitations, arising out of their respective duties with our company. The indemnification agreements provide indemnification in addition to the indemnification provided by our company's certificate of incorporation and by-laws and by applicable law. Among other things, the indemnification agreements expressly provides indemnification for Ms. Erbez and Dr. Emanuele for expenses, liability and loss (actually or reasonably incurred by each of them in connection with the investigation, defense, settlement or appeal of any proceeding relating to their respective duties with our company. In addition, we have agreed to advance expenses, subject to certain limitations, incurred by Ms. Erbez and Dr. Emanuele in connection with the investigation, defense, settlement or appeal of any proceeding to which they are a party or are threatened to be made a party as a result of their respective duties with our company.
On December 20, 2017, the Company entered into a Material and Data Transfer, Option and License Agreement (the "License Agreement") with NEOMED Institute, a Canadian not-for-profit corporation ("NEOMED"), that provides the Company with up to twelvemonths from the date of receipt by the Company of the required materials to conduct certain non-clinical research studies, diligence and technical analyses with NEOMED's proprietary therapeutic compound NEO1940 (the "Compound" and an option (the "Option") for an exclusive worldwide license to develop and commercialize products comprising or containing the Compound. In clinical development studies with NEOMED's prior sponsor, NEO1940 was dosed in over 200 subjects. The License Agreement has an effective date of January 2, 2018 (the "Effective Date").
NEOMED, without additional consideration and at NEOMED's sole cost, has agreed to deliver to the Company certain technology transfer materials and the quantity of the Compound substance specified in a research plan, both as set out under the License Agreement.
The Company will evaluate the Compound and then decide whether to exercise the Option. Upon exercise of the Option, NEOMED will provide the Company with an exclusive worldwide license under all of NEOMED's intellectual property rights covering the Compound ("Licensed IP Rights") to research, develop, make, have made, use, offer for sale, sell, have sold and import products containing the Compound and otherwise exploit the Licensed IP Rights in all fields.
On January 18, 2018, we entered into an Exclusive License Agreement (the "License Agreement") with The Research Foundation For The State University of New York, a New York nonprofit, educational corporation (the "Foundation"), that provides the Company with an exclusive license under certain licensed patents of the Foundation (the "Patent Rights") to develop, make, manufacture, have made, use, sell, have sold, import, export, and offer for sale Patent Product(s) and Other Product(s) worldwide in all fields, including without limitation the field of human therapeutics. The Agreement has an effective date of January 18, 2018 (the "Effective Date").
We are a discovery research and development stage company and have commenced only minimal business operations and have not generated any revenues. We have been issued a "going concern" opinion by our auditor, based upon our reliance on the sale of our common stock as the sole source of funds for our current operations.
We have two wholly owned subsidiaries, Trinity Reliant Ventures Limited, in Ireland, and Trinity Research & Development Limited, in England and Wales.
We have never declared bankruptcy, been in receivership, or involved in any kind of legal proceeding.
We are federally-compliant, ethical development-stage biopharmaceutical company focused on discovering, licensing, developing and commercializing treatments that modulate the endocannabinoid system. We intend to pursue technologies and programs that offer promising and proprietary compounds that promote the effectiveness of the endocannabinoid system.
As of February 28, 2018, the Company acquired a license to research-stage novel endocannabinoid modulators from Stony Brook University, New York, and the Company secured certain rights to work with a high-potency, dual CB1/CB2 agonist (NEO1940) licensed from the NEOMED Institute, Montreal, Canada. In addition, the Company discovered a novel crystalline form of cannabidiol (CBD) and filed a composition of matter patent with the USPTO in December 2017. A proprietary solid-state form of cannabidiol based upon a single polymorphic form offers the Company the opportunity to develop a cannabidiol-based drug product with the potential for improved safety and efficacy. We believe our programs have the potential to dramatically improve patient care in major markets globally, including North America and Europe.
Our board and management have experience developing and commercializing ethical pharmaceutical products, including several first-in-class drugs in multiple therapeutic areas. As we build our pipeline and advance programs through the research and development process, we expect to evaluate partnerships with large pharmaceutical and biopharmaceutical companies to collaborate on research, support clinical development, and enter into commercial licensing agreements. We intend to preserve our development and commercialization rights while embracing collaborations without hesitation in certain situations and territories where we believe there is a strong driver for maximum value creation.
To date, none of our product candidates have completed clinical development, been submitted for regulatory review or received marketing authorization from any regulatory agency. Therefore, we have not yet received revenue from the sale of any of our product candidates.
The following summary of our results of operations, for the six months ended February 28, 2018 and 2017, should be read in conjunction with our interim financial statements, as included in this Form 10-Q and our audited financial statements for the year ended August 31, 2017, as included in Form 10-K filed with the SEC on November 29, 2017.
Our financial statements have been prepared assuming that we will continue as a going concern and, accordingly, do not include adjustments relating to the recoverability and realization of assets and classification of liabilities that might be necessary should we be unable to continue in operation. We expect we will require additional capital to meet our long term operating requirements. We expect to raise additional capital through, among other things, the sale of equity or debt securities, but we cannot guarantee that we will be able to achieve same.
The following table provides selected financial data about our company as of February 28, 2018 and August 31, 2017.
We have not generated any revenues since inception through February 28, 2018. The decrease in cash was primarily due to an increase in operating expenses offset by proceeds from stock issuance.
Our operating expenses, for the three months ended February 28, 2018 were $628,354 compared to $11,995 for the same period in 2017. The Company's operating expenses were primarily related to research and development expense and professional fees for ongoing regulatory requirements.
Our operating expenses, for the six months ended February 28, 2017 were $905,411 compared to $21,512 for the same period in 2017. The higher operating expenses during the six months ended February 28, 2018 were primarily related to research and development expenses.
During the six months ended February 28, 2018, cash used in operating activities was $637,379 compared to cash used in operating activities of $22,193 during the period ended February 28, 2017. The cash used from operating activities was primarily attributed to net loss of $905,411 offset by stock based compensation of $156,001 and an increase in accounts payable and accrued liabilities of $125,635.
The company did not use any funds for investing activities in the six months ended February 28, 2017.
During the six months ended February 28, 2018, the company received $592,137 from the issuance of common shares, $16,583 as an advance from a related party, and repaid $15,843 to a related party. During the six months ended February 28, 2017, the company received advances from shareholders of $100 and proceeds from issuance of note payable of $29,400.
Our auditors issued a going concern opinion on our financial statements as of and for the period ended August 31, 2017. This means that there is substantial doubt that we can continue as an on-going business for the next twelve months unless we obtain additional capital to pay for our expenses. This is because we have not generated sufficient revenues to cover operating costs or raised enough funds. There is no assurance we will ever reach this point. Accordingly, we must raise sufficient capital from sources. We must raise cash to stay in business. In response to these problems, management intends to raise additional funds through public or private placement offerings.
We do not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. In addition, we do not have any undisclosed borrowings or debt, and we have not entered into any synthetic leases. We are, therefore, not materially exposed to any financing, liquidity, market, or credit risk that could arise if we had engaged in such relationships.
We prepare our financial statements in conformity with GAAP, which requires management to make certain estimates and apply judgments. We base our estimates and judgments on historical experience, current trends and other factors that management believes to be important at the time the financial statements are prepared. On a regular basis, we review our accounting policies and how they are applied and disclosed in our financial statements.
Our management, with the participation of our CEO (our principal executive officer, principal financial officer and principal accounting officer), has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a- 15(e) and 15d- 15(e) under the Securities Exchange Act of 1934, as amended (Exchange Act)), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, our CEO (our principal executive officer, principal financial officer and principal accounting officer) have concluded that as of such date, our disclosure controls and procedures were not effective such that the information relating to us required to be disclosed in our Securities and Exchange Commission ("SEC") reports (i) is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and (ii) is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure.
From time to time, we may become involved in litigation relating to claims arising out of its operations in the normal course of business. We are not involved in any pending legal proceeding or litigation and, to the best of our knowledge, no governmental authority is contemplating any proceeding to which we are a party or to which any of our properties is subject, which would reasonably be likely to have a material adverse effect on us.
Investing in our common stock involves risk. Before making an investment in our common stock, you should carefully consider the risk factors discussed in Part I, Item 1A, "Risk Factors" of our Form 10-K for the year ended August 31, 2017. The risks described in the Form 10-K are those which we believe are the material risks we face, and such risks could materially adversely affect our business, prospects, financial condition, cash flows and results of operations. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may impact us. Except as set forth below, there have been no material changes in our risk factors from those previously disclosed in the Form 10-K.
If we fail to comply with our obligations to our licensor in our intellectual property license, we could lose license rights that are important to our business.
We are a party to the NEOMED Agreement, and we may enter into additional license agreements in the future. Our existing license agreements impose, and we expect that any future license agreements will impose, various diligence, product payment, royalty, insurance and other obligations on us. If we fail to comply with these obligations, our licensors may have the right to terminate these agreements, in which event we might not be able to develop and market any product candidate that is covered by these agreements. Termination of these licenses or reduction or elimination of our licensed rights may result in our having to negotiate new or reinstated licenses with less favorable terms. The occurrence of such events could have a material adverse effect on our business, financial condition and results of operations.
Even if we are successful in licensing or developing research programs and/or product candidates, we or our licensors must maintain the intellectual property.
Our commercial success is significantly dependent on intellectual property related to any product candidates and technologies we may either acquire, license or develop internally. We are currently the exclusive world-wide licensee of specific endocannabinoid modulators developed at Stony Brook University in New York and we licensed an option to the patents covering NEO1940 from the NEOMED Institute, Montreal, Canada. We intend to continue to license additional intellectual property from biopharmaceutical companies and research institutions. In addition, based upon our own discovery research initiatives, we filed a provisional patent application on December 11, 2017 on novel chemistry related to a cannabiol composition. We have not received action on any of the provisional application as a result of our own research efforts.
Our success depends in large part on our and our licensor's ability to obtain and maintain patent protection in the United States and other countries with respect to our proprietary technology and product candidates. In some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology or products that we license from third parties. Therefore, we cannot be certain that these patents and applications will be prosecuted and enforced in a manner consistent with the best interests of our business. In addition, if third parties who license patents to us fail to maintain such patents, or lose rights to those patents, the rights we have licensed may be reduced or eliminated.
The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our and our licensor's patent rights are highly uncertain. Our and our licensor's pending and future patent applications may not result in patents being issued which protect our technology or products or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. The laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we or our licensor were the first to make the inventions claimed in our owned and licensed patents or pending patent applications, or that we or our licensor were the first to file for patent protection of such inventions. Assuming the other requirements for patentability are met, the first to file a patent application is entitled to the patent. We may become involved in opposition or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such proceeding could reduce the scope of, or invalidate our patent rights, allow third parties to commercialize our technology or product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize our product candidates without infringing third-party patent rights.
Even if any owned and/or licensed patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner. The issuance of a patent is not conclusive as to its scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop or prevent us from stopping others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.
On January 2, 2018, the Company issued 120,000 shares of its common stock valued at $126,000 to NEOMED for services.
During the six months ended February 28, 2018, the Company received cash of $582,136 that has been recorded for the issuance of 895,587 common shares at a price of $0.65 per Unit pursuant to a private placement offering conducted by the Company in relation to subscription agreements accepted on January 26, 2018 and March 15, 2018. Each Unit consists of: (i) one (1) share of common stock; and (ii) one (1) Series A Stock Purchase Warrant to purchase one (1) share of common stock at a price of $1.50 per share for a period of 5 years from the issue date.


DIY Home Surveillance with ABOX IP Camera: If you're looking to tighten up your home security on the cheap or you want to set up a monitoring system in your home or families home then ABOX IP Camera has a cam for an affordable price. The camera is pretty good and has loads of features which are listed below. I will show you how to set up your camera in this video and show you the features it has.
Importance: The camera only works with 2.4GHz network (Incompatible with 5GHz), wired connection also included.
Deepcool Captain 240EX RGB Sync AIO CPU Water Cooler: Worth Buying?
Cheap Dash Cam – Are They Any Good?


Dr. Jose Pozo is Director of Technology and Innovation at EPIC (European Photoni cs Industry Consortium). As EPIC's CTO, he represents 350 companies active in the field of Photonics. His job consists on actively engaging with them and provide them with tools to strengthen their position in the supply chain; such tools are the organization of 20 technology workshops per year, provision of market intelligence and finding B2B leads. He has the vision that the future of optoelectronic manufacturing can take place in Europe to a large extent, and as part of that vision he is actively involved in the EU-funded pilot lines. He has 20 years' background in photonics technology, market knowledge, and a large network within the industrial and academic photonics landscape. Dr. Pozo holds a Ph.D. in electrical engineering from the University of Bristol, U.K., and a M.Sc. and B.Eng. in telecom engineering from UPNA (Spain) / VUB (Belgium). In addition, Dr. Jose Pozo has worked as post-doctoral researcher at the Eindhoven University of Technology (The Netherlands), EU proposal coordinator at TNO (The Netherlands), and Sr. Photonics Technology Consultant at PNO Consultants.


text:
Sixth District Rep. Ben Cline to host Augusta County town hall
Claire Mitzel
The News Leader
STUARTS DRAFT — Sixth District Rep. Ben Cline will host an Augusta County town hall next week in Stuarts Draft to listen to constituents' concerns and opinions.
The event will take place from noon to 1:30 p.m. on July 9 at the Stuarts Draft Veterans of Foreign Wars Post 9339, 3251 Stuarts Draft Highway.
"I look forward to meeting with the citizens of Augusta County next week," Cline said in a news release. "As with my previous town hall meetings across the Sixth Congressional District, this town hall will allow me to engage with Augusta County residents and take their views to Washington."
The release said Augusta County residents will be given priority to make comments. Noisemakers and signs are prohibited, according to the release.
Cline, a Republican, was elected in November 2018 to the House of Representatives, defeating Democrat Jennifer Lewis. He filled former Republican Rep. Bob Goodlatte's seat, who left after 13 terms. Cline previously served in the Virginia House of Delegates for 16 years as the 24th district's delegate, according to previous News Leader reporting.
Subscribe: Stay up to date on local government and watchdog news. Click here to subscribe.
I want to hear from you! Send me a note at cmitzel@newsleader.com or call at 255-9980 if you have a question or a story idea, and follow me on Twitter @c_mitzel.

redpajama_set_name: RedPajamaCommonCrawl


text:
Mongolia – The Bank Of Mongolia Issues Revised Version Of The Bank Licensing Regulations.
Legal News & Analysis – Asia Pacific – Mongolia
On 7 June 2012, the Bank of Mongolia adopted regulations on bank licensing (the "Bank Licensing Regulations") to implement certain provisions of the Banking Law of Mongolia dated 28 January 2010 (the "Banking Law"). These regulations replace the regulations on bank licensing dated 7 August 2000. The newly-adopted regulations were officially published on the Bank of Mongolia website on 2 July 2012.
The promulgation of regulations consistent with the Banking Law had been pending for several months, and their issue should help to clarify uncertainties relating to the procedural aspects of the approvals and notifications process at the Bank of Mongolia.
The scope of the Bank Licensing Regulations is regulation of matters relating to applications to the Bank of Mongolia for establishing a bank, conducting banking activities, changing a bank's shareholding structure and share capital, and the review of such applications and supporting documents.
The regulations further clarify certain definitions, specify the requirements for establishing a wholly-owned subsidiary of a foreign bank in Mongolia and the circumstances in which banking licences may be issued, restricted, suspended, or revoked.
With respect to the entry of foreign banks into the Mongolian market, the Bank Licensing Regulations impose greater restrictions. Currently, it is not possible for foreign banks to operate through their branch offices in Mongolia, as under
Mongolian law it is prohibited for representative and branch offices to engage in revenue-generating activities. The Bank Licensing Regulations contemplate the establishment of wholly-owned subsidiaries of foreign banks and provide detailed requirements and procedures for setting up such subsidiaries. Foreign banks may establish local subsidiaries no earlier than one year after the establishment of their Mongolian representative offices. Accordingly, the establishment of a representative office is a prerequisite for establishment of a local subsidiary.
Further, the minimum share capital requirement for a Mongolian subsidiary of a foreign bank is set at MNT65 billion (US$50 million), which is much higher than the minimum capital requirement for an existing Mongolian bank (currently US$6 million and set to increase to US$12 million from 1 May 2013). This requirement is set out in Order # A-81 of the President of the Bank of Mongolia dated 7 June 2012.
According to Article 1.5.3 of the Bank Licensing Regulations, share capital is defined as "the sum of total par value of the bank's issued common and preferred shares and any share premium, which shall consist of the capital contributions made by shareholders as approved by the Bank of Mongolia". Thus, the share capital cannot take into account treasury stock.
Michael Aldrich, Partner, Hogan Lovells
Chris Melville, Partner, Hogan Lovells


The Mom Genes campaign by Galderma.
Interview with Dr. Ben Tittle on how daughters can look to your mother on how you will age.
Airdate: June 12, 2016 on lifestyle show "Live Love Laugh Today with Linda Cooper & Susie McAuley", ABC Network WFAA-8.


text:
Camil Plàcid Crous i Salichs, O.F.M.Cap. (Calella, 16 de gener de 1896 – Barcelona, 20 de gener de 1985) va ser un frare i bisbe català.

Als setze anys ingressà a l'Orde de Framenors Caputxins, en el convent de Sarrià (Barcelona) de la qual feu estudis de teologia i pronuncià els seus vots perpetus el 1917. El 20 de desembre de 1919 fou ordenat sacerdot a la catedral de Barcelona de mans del bisbe Enric Reig i Casanova.

Des de 1905 i per acord entre la Santa Seu i el govern colombià, l'ampli territori del sud-est del país, habitat per indígenes de les ètnies andakí i camsá i cobejat per la seva riquesa en cautxú, estava confiat a l'Orde Caputxí de la província de Catalunya. En un dels viatges a Barcelona dels frares pioners fra Fidel de Montclar (Josep Pujol i Coll) i fra Estanislau de Les Corts (Pere Sitjà i Basté) per a la captació de nous missioners aconseguiren de convèncer Crous, el qual viatjà per primera vegada a Amèrica l'any 1922. Després d'una breu estada a Panamà passà a Colòmbia.

Allí desenvolupà la seva missió per tot el territori anomenat Comisaría Especial de Amazonas e Intendencias de Caquetá i Putumayo, en el qual els caputxins regentaven deu parròquies i nombroses escoles i hospitals, alhora que promocionaven importants obres públiques, sovint enfrontant-se a les apetències del Perú sobre la zona i als interessos dels explotadors de les seves riqueses forestals.

El 6 de juliol de 1947, a la catedral de Bogotà, Camil Plàcid Crous fou consagrat bisbe titular de Cratia de mans del nunci mons. Giuseppe Beltrami i nomenat vicari apostòlic de Caquetá. Quatre anys després, i ran de la redistribució eclesiàstica de la zona, passà a regentar el vicariat apostòlic de Sibundoy. En aquesta localitat erigí el seminari menor i fundà les primeres escoles de secundària;.

Assistí a les quatre sessions del Concili Vaticà II.

A causa d'un important malaltia vascular, hagué de dimitir del vicariat apostòlic el 16 de gener de 1971 i tornà a Catalunya, passant a residir al convent dels Caputxins de Sarrià, on romangués fins a la seva mort.

Referències

Calellencs
Bisbes catalans
Caputxins catalans
Religiosos maresmencs
Participants al Concili Vaticà II
Caputxins de Sarrià
Franciscans catalans del sud contemporanis
Morts a Barcelona

redpajama_set_name: RedPajamaWikipedia


Submissions are open for the Ravello Tales Award 2018. Anyone can compete sending - by the 15th of November 2018 - a short narrative in English inspired by Ravello (12.000 words as an indication) together with his/her bionote (150 words) and the signed declaration of Acceptance quoted at the bottom of the terms and conditions.
The award will consist of the publication of the winning short narrative, plus a 1-week stay in Ravello (for two persons), in one of the hotels of the Consorzio Ravello Sense.
Additional narratives, even if not awarded, may be included in the final publication, at the Consorzio's discretion. See the terms and conditions of Ravello Tales Award. Further infomation on www.visitravello.com.


text:
British Textile Biennial
Patrons and Partners
3rd October - 3rd November 2019
The Mr X Stitch Guide to Cross Stitch
Date: Thursday 3rd October – Friday 28th February 2020
Opening times: Saturday to Thursday, 12–5pm (last entry 4pm)
Venue: Towneley Hall
Entry: Entry to the hall is £5 or free if you have a 12-month pass
The Mr X Stitch Guide to Cross Stitch aims to change the way you think about this simple embroidery.
There is a pre-conception that cross stitch is an out-of-date pastime where people stitch wistful images of a bygone era, and while that is partly true, it is the tip of the cross-stitched iceberg.
While archive pieces from the Royal School of Needlework remind you of the historical context of needlecraft, the exhibiting artists that were on show use cross stitch to explore politics on international and interpersonal levels, as well as explore pop culture, contemporary design and the darker side of life.
Jamie Chalmers, aka Mr X Stitch, aka the Kingpin of Contemporary Embroidery, took up cross stitching fifteen years ago and he's never looked back.
Since establishing the Mr X Stitch website in 2008, he has been showcasing new talent in the world of textiles and stitch and has curated a number of stitch-based exhibitions in the UK and Ireland. Jamie is an accomplished and internationally exhibited artist in his own right, the curator of PUSH Stitchery and the author of the Mr X Stitch Guide to Cross Stitch. He is the founder of the game-changing XStitch cross stitch design magazine which launched in Summer 2017. Jamie loves introducing new people to the benefits of embroidery from a creative and wellbeing standpoint and is proud to be an ambassador for this ubiquitous craft.


IIM Calcutta Innovation Park in association with the TATA group hosted the Thinking Social Seminar at the International Management Institute, on 4th Dec,2017. The primary objective of this event was to build awareness on social entrepreneurship, generating interest and inspiring the youth to come up with innovative solutions to prevalent social challenges. The speakers at the seminar comprised of eminent and social entrepreneurs, investors and members of the academic field being individuals who have been accredited of having established their own outstanding ventures creating a strong social impact. The panel at the event comprised of seasoned entrepreneurs including Dileep Kumar (Tata Power Delhi), Suman Mukhopadhyay(Director – Banglanatak.com), Arun Nagpal (Founder – Mrida), Anirban Gupta(Founder – Dhriiti), Pawan Mehrotra(Founder – Aarna Biomedical Products Pvt. Ltd) and Neha Arora(Founder – Planet Abled).
Mr. Dileep Kumar cheered the inaugural session mentioning the activities TATA Group had undertaken till date. Mr. Suman Mukhopadhay enlightened the audience about aspects of Social Entrepreneurship and relevance of smart solutions to solve development challenges, Clarity was brought about to the concept of 'social entrepreneurs' being entrepreneurs who aim to solve prevalent societal problems, either for-profit or non profit..
Mr. Arun Nagpal spoke about his journey as an entrepreneur . His journey that started a decade ago wherein he believed that not all the solutions to India's problems could come from the government or a body Corporate. Mr. Nagpal stated that he believed in solutions to prevalent social issues to be brought about by entrepreneurs, individuals who have had a strong relationship with an issue and are committed to designing a solution for it. Explaining his venture 'Mrida' having its nomenclature roots in Sanskrit which meant 'Soil' Mr. Nagpal explained that, the single word encapsulates what they stand for which would be working at the ground level, close to the soil, their work being directed mainly the Base of the Pyramid (BOP) individuals being their core customers.
Speaking about his venture Anirban Gupta Founder of 'Dhriiti – The Courage Within' an NGO (social enterprise) registered under the Societies Act of 1860 established in December 2004 by Anirban and two other members. Anirban elaborated about Observing the problem of unemployment and underemployment in the country at large, and contemplating on how these problems could be tackled in the long run as well as providing immediate solutions .. He inferred that the problem of unemployment, disguised unemployment and underemployment cannot be dealt with, at all levels by creating more jobs in the government and the high investment public/ private sector.
The Founder believes that self-employment and entrepreneurship is an important tool to counter the problem of widespread unemployment and underemployment in the country. The core idea behind Dhriiti as he spoke was the spirit of entrepreneurship that we want to promote, introduce and inculcate. Dhriiti works from the two ends of the continuum to spread a culture of entrepreneurship.
Mr.Pawan Mehrotra Founder of Aarna Biomedical Products Pvt. Ltd a social entrepreneurship start-up, shared his experience and journey as an entrepreneur.
Neha Arora Founder of Planet Abled affirmed that the world is nostalgic, whether we just feel it through our five senses or experience it wandering on a wheel chair or our own feet. She said and we quote "This world is for everybody, whosoever it is. We should explore the world with an open mind, without any hindrance".
Further explaining her inspiration for her venture Neha spoke "My personal not so good travel experiences as a daughter of parents with disabilities led to the inception of Planet Abled. Mfather is blind and mother is a wheelchair user, but we all are fond of traveling." The zeal to travel but the difficulties that she had faced while travelling lead her to break every barriers and create her own travel agency for disabled people.
The seminar concluded with an interactive Q & A session, where questions were posed by the students and faculty members.
IIM Calcutta Innovation Park in association with the TATA group hosted the Thinking Social Seminar at IITM Research Park, Chennai, on the 21st November. The primary objective of this event was to build awareness on social entrepreneurship, generate interest and inspire the youth to come up with innovative solutions to social challenges. The speakers of the seminar comprised of eminent and social entrepreneurs, investors and members of the academic field who have established their own outstanding ventures touching the lives of thousands ..
The seminar commenced following a welcome address by Mr Gaurav Kapoor. Mr. Gaurav Kapoor emphasized on the subject of being a social entrepreneur he added and we quote "Being social doesn't just mean being on the social media but also being Social in the true sense of the word. A social entrepreneur is a person who pursues novel applications that have the potential to solve community-based problems. These individuals are willing to take on the risk and effort to create positive changes in society through their initiatives".
Mr. Sabarinath C the Founder CEO of Skillveri Training Solutions Private Limited,spoke about his venture which helps in addressing India's Skill Gap. Skillveri enables better quality delivery of practical vocational skill training at significantly lesser costs through its innovative, scalable platform of multi-skill simulators. The Venture has recently graduated from IIT Madras' Rural Technology and Business Incubator (RTBI). During current times Skillveri has established itself as a market leader in the sector with a range of welding-training products and new offerings like spray painting, gold -jewelry soldering and medical skills.
Mr. Kalyan Sivasailam (CEO – 5C Network) shared his experience about his journey as an entrepreneur. 5c Network being a technologically driven advanced telehealth platform focusing on Remote Radio diagnosis, offers the highest quality radiological interpretations at the fastest possible time. They connect the best radiologists to hospitals and diagnostic centers, thus solving the problem concerning lack of qualified radiologists at every hospital or diagnostic centers,. It is their innovative technology and business model, that makes 5C Network unique in the telehealth platform. They are India's first diagnostic network, and their vision is to bridge India's healthcare divide.
Lastly Mr. Pradeep Thangappan the Founder of Enability Foundation For Rehabilitation, spoke about his venture which focuses on providing indigenous and affordable assistive technology solutions for rehabilitation workers, teachers, schools and resource centers. Their product iGest, captures gestures of children with cerebral palsy and converts them into a dictionary of sentences.
IIM Calcutta Innovation Park in association with the TATA group hosted the Thinking Social Seminar at T-Hub, Hyderabad November 20th, 2017. The primary objective of this event was to build awareness on social entrepreneurship, generate interest and inspire the youthto come up with innovative solutions to social challenges. The speakers of the seminar comprised of eminent social entrepreneurs, investors and academicians who having established their own outstanding ventures and having an impact on the lives of thousands ..
of Banglanatokdotcom ,Mr. K.C .Mishra, Founder E-Kutir, Mr.Binayak Acharya- Founder,Tatvagyan ,Mr. Amar Kr Jamdhiar- Founder &CEOProsperita Medi360 Pvt Ltd, Ms.Ambika Satpathy- Co Founder,Zoofresh and Mr.Sanjib Parida – Founder,Orbonix.
Mr. Suman Mukhopadhay chaired the session highlighting Social Entrepreneurship and the relevance of smart solutions to solve development challenges. He emphasized on the fact that today the social Entrepreneurs have a number of opportunities in their disposal and as such should be equipped to handle any situation and innovation that ultimately will lead to a solution as was mentioned earlier in the session by Mr. K.C .Mishra, Founder E-Kutir.
The seminar ended with an interactive Q & A session, where questions were posed by the students and faculty members.
IIM Calcutta Innovation Park in association with the TATA group hosted the Thinking Social Seminar at T-Hub, Hyderabad on November 20th, 2017. The primary objective of this event was to build awareness about social entrepreneurship, generate interest and inspire the youth to come up with innovative solutions to social challenges. The speakers of the seminar comprised of eminent and social entrepreneurs, investors and members of academia having established their own outstanding ventures having an impact on the lives of thousands ..
The panel of speakers comprised of esteemed entrepreneurs including Mr, Gaurav Kapoor: (Serial Social Entrepreneur), Mr. Brig P Ganesham Founder – President, Mr. Palle Srujana Prashant Lingam Co-Founder, Bamboo House India; Dr. Praveen Kumar SecretaryTelangana Social Welfare Residential Educational Institutions Society (TSWREIS).
The seminar commenced following a welcome address by Mr Gaurav Kapoor, emphasizing on what it means to be social entrepreneur he added and we quote "Being social doesn't just mean being on the social media but also being Social in the true sense of the word. A social entrepreneur is a person who pursues novel applications that have the potential to solve prevalent community-based problems. These individuals are willing to take on the risk and effort to create positive changes in society through their initiatives".
Brig P Ganesham Founder – President, Palle Srujana spoke about villagers who have their own knowledge and ways of expression. Stating facts that traditional knowledge of the villagers has been ignored and the rural people are not able to cope with modern knowledge being disruptive. Its urban populations responsibility to bring their usefulknowledge back by engaging in conversation with the rural people. The speaker said and we quote "The whole world is run by the people and for the people, henceforth we shouldn't be dependent on the machine, we should extend our hand and help the farmers". He mentioned that to become a social entrepreneur one needs to first become a coachable individual and have the right kind of skills set.
Later Mr. Prashant Lingam Co-Founder, Bamboo House India spoke about his journey in social entrepreneurship. Bamboo House India is a social enterprise established by two first generation entrepreneurs Prashant Lingam ( Management Graduate) and Aruna Kappagantula (Science Graduate) in the year 2008 with an aim of utilizing bamboo as an economic driver for providing sustainable livelihood opportunities to rural and tribal communities dependent on bamboo for livelihoods and at the same time utilize bamboo as a eco friendly substitute for wood , steel, iron steel and plastic thus establishing the – Bamboo House in Hyderabad.
Lastly spoke Dr. Praveen Kumar Secretary, Telangana Social Welfare Residential Educational Institutions Society (TSWREIS) about the zeal a social entrepreneur should have. He emphasized on the fact that a social entrepreneur should be ambitious and persistent, tackling major social issues and offering new ideas for wide-scale change.
The seminar ended with an interactive Q & A session, where questions were posed by students and faculty members.
SMART FIFTY :IMCIP & DST(Department of Science and Technology) launches Smart Fifty which is aligned to 'Start-Up India' movement and aims to promote socio-economic development in India. Smart Fifty is probably the biggest Start-Up hunt in India to identify, recognize and reward aspiring and early-stage entrepreneurs. The platform will focus on innovative ideas which can transform India from a socio-economic perspective, urging participants to present solutions that are SMART(Sustainable, Motivating, Affordable, Responsible and above all,Transformative).
IIM Calcutta Innovation Park in association with the TATA group and Bihar Entrepreneur Association hosted the Thinking Social Seminar at Chanakya National Law University on 22 July 2017. The primary objective of this event was to build awareness on social entrepreneurship, generate interest and inspire the young generation to come up with innovative solutions to social challenges. On 21st July 2017 we had organized a business plan pitching session for social entrepreneurs in Bihar. 80 startups had applied for this and only 20 startups were shortlisted to participate in this event.
The speakers of this seminar comprised of eminent and social entrepreneurs, investors and academicians who have already established their own outstanding ventures and have impacted the lives of thousands of people.
The seminar commenced with the welcome address by Mr Abhishek Singh, Secretary General – Bihar Entrepreneur Association who spoke about how BEA was formed and the kind of work they are doing in the state of Bihar. He mentioned, " We are a regional coalition of entrepreneurs, business and community leaders, organizations and local government dedicated to provide start-ups of Bihar with access to nationwide tools and resources that will help them scale up." He also spoke about the Bihar Startup Yatra's which they have been organizing in partnership with the Department of Industries, Govt. of Bihar since 2011.
Mr. Vikram Duggal, Unitus Seed Fund spoke about the funding opportunities available to start-ups in the social entrepreneurship space.
Mr Kaushlendra, Co-founder Samriddhi and President Bihar Entrepreneur Association spoke about the scope of social entrepreneurship in Bihar & Jharkand. He also explained to the audience the importance of technical knowledge.
The seminar ended with an interactive Q & A session and the names of the top 3 winners of the Business Plan Pitching Session held the previous day were declared.
TakGi: They are bridging the gap between the retailer and wholesaler for sourcing medicines, which is a major pain point, by assigning a dedicated staff who is required to source the medicines on a daily or weekly basis.
The Ganna Cafe: The Ganna cafe provides freshly prepared hygienic and healthy sugarcane juice through a vending cart. This is done through a motorized machine in a single crush process. The ganna juice which they provide is hygienic, healthy and cost effective i.e. at par with the current market rate.
R-Labs: They help engineering students to test their robotic programming on high end, state of art Robots which are located at various premium universities in Europe.
IIM Calcutta Innovation Park in association with the TATA group hosted the Thinking Social Seminar at Pacchunga University College on March 31st, 2017. The primary objective of this event was to build awareness on social entrepreneurship, generate interest and inspire the young generation to come up with innovative solutions to social challenges. The speakers of the seminar comprised of eminent and social entrepreneurs, investors and academicians who have already established their own outstanding ventures and have impacted the lives of thousands of people.
The seminar commenced with the welcome address by Dr. C. Vanlalramsanga, IES, Secretary Planning Department and Alternate Chairman of Mizoram State Entrepreneurship Development Monitoring Committee (MEDMOC) who spoke about the various initiatives which the Mizoram government has been taking up on Entrepreneurship Development. He also urged the students to take inspiration from these social entrepreneurs so that they can take up entrepreneurship as a career option.
Prof. C D Mitra, IIM Calcutta spoke about who is a social entrepreneur and how to identify gaps and create a business opportunity out of it. He said, "Being an entrepreneur is not only about starting your own venture, It is essentially finding a gap between what is and what should be. The moment you find a smart way to bridge that gap connected to a social problem and you create a business opportunity, you become a social entrepreneur." He urged the students to innovatively solve some of the unsolved problems in the state.
Mr. Vikram Duggal, Unitus Seed Fund said, "There are so many unresolved problems, especially in the North-Eastern regions of India. Social Entrepreneurs have tremendous opportunity to create profitable businesses and impact lives of underserved masses at same time. He also added that at Unitus Seed fund they need to see traction, among other things, before investing in any startup. Ten of the portfolio companies have raised series A and two have raised series B funding.
Mr Gaurav Kapoor, Innokul, spoke about the various social issues plaguing our nation in the health, environment, education, population and employment sectors and how youth can take cognizance of these issues and come up with relevant indigenous solutions. He inspired the youth with videos of live examples of social enterprises that have solved some mammoth social challenges in their respective sectors. He also gave the audience a deep insight into the concept of social enterprises and how they function.
The seminar ended with an interactive Q & A session, where questions were posed by not only the students but faculty as well.
IIM Calcutta Innovation Park in association with the TATA group hosted the Thinking Social Seminar at Shiv Nadar University on April 8th, 2017. The primary objective of this event was to build awareness on social entrepreneurship, generate interest and inspire the young generation to come up with innovative solutions to social challenges. The speakers of the seminar comprised of eminent and social entrepreneurs, investors and academicians who have already established their own outstanding ventures and have impacted the lives of thousands of people.
The seminar commenced with the welcome address by Prof. Partha Roy, Professor at School of Management and Entrepreneurship (SME), Shiv Nadar University. He was very happy with this initiative which they have conducting for the last three years.
Prof. C D Mitra, IIM Calcutta spoke about who is a social entrepreneur and how to identify gaps and create a business opportunity out of it. He said, "The world is full of social problems which need to be solved. An entrepreneur who tries to solve these problems through his venture is a social entrepreneur." He also conducted a small session with the students where he asked them to identify some problems in the country and think of a solution to overcome the problems. The students were very enthusiastic and came up with problems like – Pollution, Illiteracy, Mental Health, Poor conditions of the farmers, infant mortality etc.
Neha Arora, Founder – Plantet Abled spoke about her venture and how she is helping the community with people having disabilities. She gave an insight to the audience about the lives and challenges of people with disabilities and hoped that they would now be empathetic and observant about how simple things can be path breaking for someone.
Kapil Mandawewala, Founder – Edible Routes, shared with the audience about how he started his venture after returning from the U.S as a consultant. Kapil had a keen interest in the agri-business sector which helped him to start Edible Routes. He mentioned that, "We don't know where the food we eat is grown or what chemicals are used to grow it." His organization – Edible Routes – conducts kitchen gardening workshops for adults and school children and they also set up kitchen gardens to help people grow their own vegetables and reconnect with nature.
Dr Avijit Chakrabarthi, Founder – Bindubot, started by giving a simple definition of a social enterprise. He said, "To combine a social objective with a business formula is a social enterprise." He also mentioned that. "Unless there is passion in the entrepreneur, the venture will not work." Dr Chakrabarthi also spoke about how Bollywood is the biggest social enterprise in our country as it highlights (though it's movies) some of the most prevalent social issues like – Poverty, unemployment, homelessness and other social issues.
IIM Calcutta Innovation Park in association with the TATA group hosted the Thinking Social Seminar at XIM, Bhubaneswar in partnership with e-Kutir and PNV foundation as part of the GSIS (Glocal Social on February 18th, 2017. The primary objective of this event was to build awareness on social entrepreneurship, generate interest and inspire the young generation to come up with innovative solutions to social challenges. The speakers of the seminar comprised of eminent and social entrepreneurs, investors and academicians who have already established their own outstanding ventures and have impacted the lives of thousands of people.
The speakers consisted of an esteemed panel of entrepreneurs including Mr. K M Mishra, Founder, e-Kutir; Smita Agarwal – Head CSR, Tata Steel; Mr. Jaynarayan Pujapanda, Founder, Sahaya Foundation; Mr. Joe Madiath – Founder Gram Vikas, and Tanaya Patnaik, Executive Director Sambad Group.
Mr. Jaynarayan Pujapanda, Founder, Sahaya Foundation shared with the audience his inspiring journey from a sales person to an entrepreneur. He mentioned that to become a social entrepreneur one needs to first become an entrepreneur and have the right kind of skills set. He also spoke about how Paris Bakery, his profit venture has helped him to establish Sahaya Foundation.
Mr K C Mishra, Founder – e-Kutir spoke about how social business is the need of the hour not only in extending marketing based principles but also a career opportunity for the youngsters.
Dr. Birupaskshya Dixit, Practical Action spoke about how his organization is supporting social enterprises in Orrisa. His organization finds out what people are doing and helps them to do it in a better way. Through technology they enable poor communities to build on their skills and knowledge to produce sustainable and practical solutions- transforming their lives forever and protecting the world around them.
Tanaya Patnaik, Executive Director Sambad Group interacted with the students and expressed her views on social entrepreneurship. She spoke about her ventures like – Sambad School of Media and Culture, Kanak News and Sambad newspapers and how these have contributed to social activities.
The post lunch session started with 10 pitches from various entrepreneurs to a panel of judges whose ideas were shortlisted by XIMB and PNV foundation. There were many ideas which were generated to address the problems in various sectors like: agriculture, e-commerce solutions, healthcare services, education and other social problems of society. Three best ideas were awarded by the jury members.
IIM Calcutta Innovation Park in association with the TATA group hosted the Thinking Social Seminar at Symbiosis Institute of Media and Communication (SIMC), Lavale, Pune on January 30th, 2017. The primary objective of this event was to build awareness on social entrepreneurship, generate interest and inspire the young generation to come up with innovative solutions to social challenges. The speakers of the seminar comprised of eminent and social entrepreneurs, investors and academicians who have already established their own outstanding ventures and have impacted the lives of thousands of people.
The speakers consisted of an esteemed panel of entrepreneurs including Mr. Pradeep Lokhande, Founder and CEO – Rural Relations; Mr. Ramesh Menon, a veteran journalist, author, documentary film maker and a corporate trainer and a recipient of Ramnath Goenka Award for Excellence in Journalism; Mr. Shekhar Prabhakar, Co-founder – Hasiru Dala Innovations; Mr. Sushanth Kodela, Co-founder – Uncancer India, and Ms. Janhavi Joshi, Co-founder – Bleetech.
The seminar commenced with the welcome address by Dr. Ruchi Jaggi, Director of SIMC, who praised the initiative for bringing a social dimension to innovation and entrepreneurship.
Mr. Lokhande started off the technical sessions by recounting his journey from transforming a small idea to what is now known as Gyan Key, a rural library. The story of Mr.Lokhande is that of a humble entrepreneur, who's passion drove the project which was a very strenuous process with no immediate returns on efforts put in. He urged aspiring innovators to create not for demand by for need.
The last speaker of the day was Ms. Janhavi Joshi, who co-created an app that answered one simple problem: what if there was no music? Her innovation, Blee, allowed deaf dancers to hear music through vibrations. Although it was success, she spoke about the need for this type of technology to branch out to other aspects of life that could benefit their community. She expressed the need for technology like this, since there's no innovation for the deaf community but there are technological advances for menial things in life. The duo's main aim is the make affordable tech for a community that truly deserves it.


RJ O'Brien Building Contractors was founded by the late Ray O'Brien in 1969 (trading as Ray O'Brien Building Contractors). A proud family business based County Cork, it is now run by his son John O'Brien.
We are a small-medium sized general building contracting company. While much of our business is in the Cork and Munster area we operate a nationwide 24/7 service.
We specialise in project management and building maintenance in all trades from carpentry and decorating to electrics and plumbing to specialty trades as required.
We have a strong dedicated and loyal team that has been a major contribution to the success of our business over the years. We have the expertise, resources and personnel to undertake projects from small to large scale.
Our reputation is built on the highest level of quality and our commitment to provide industry leading building services to our customers. Our ability to meet challenges and deliver projects on time and within budget is reflected in our high levels of repeat business and our long-term client relationships.


The Materials Science Tetrahedron shows the four main areas in which materials are studied. It often includes Characterization at the center.
Materials science is an interdisciplinary field involving the study of different types of materials and the applications of knowledge about these materials to various areas of science and engineering. It combines elements of applied physics and chemistry, as well as chemical, mechanical, civil and electrical engineering. Materials science and materials engineering are often combined into a larger field of study.
Materials used in early human history included metals, glasses, and clay-based ceramics. The past century has witnessed a surge in the development of new materials, including plastics, advanced ceramics, semiconductors, superconductors, liquid crystals, Bose-Einstein condensates, and nanoscale substances, with a wide range of applications. Furthermore, materials science has grown to include testing these more exotic forms of condensed matter and developing new physics theories to explain their behavior. Consequently, materials science has been propelled to the forefront at many academic institutions and research facilities.
Materials research at the basic level can lead to unprecedented influence on society. For example, semiconductor materials, which are ubiquitous in cars, telephones, computers, clocks, kitchen appliances, children's toys, satellites, telescopes, and more, were a product of materials science research—into the electronic properties of the element germanium. Further research led to the replacement of germanium with the less costly silicon and to diverse approaches to modifying silicon's properties by implanting other elements, such as phosphorous or boron, into the silicon matrix. Since their discovery in 1947, semiconductors have been steadily improved through materials science research driven by ever-increasing performance demands from the computer industry.
Efforts to apply ethical considerations to Materials Science quickly reach what is a common barrier between ethics and the combined fields of science and technology. An individual scientist, for example, who would want to conduct research toward such a noble goal as developing a light-weight and durable structural plastic that is readily recyclable must first either find and join a research group that is already funded to support such research or find an independent funding source for such research.
Materials science is one of the oldest forms of applied science and engineering. In the history of human civilization, different eras have often been retrospectively identified according to an advance in the human ability to work with a new type of material. Examples are the Stone Age, Bronze Age, and Iron Age. A major breakthrough in the understanding of materials occurred in the late nineteenth century, when Willard Gibbs demonstrated that thermodynamic properties relating to atomic structure in various phases are related to the physical properties of a material.
Before the 1960s, (and in some cases decades after), many materials science departments at academic and research institutions were named metallurgy departments, because the emphasis was on the study of metals and their uses. The field has since broadened to include every class of materials, such as ceramics, polymers, semiconductors, superconductors, superfluids, magnetic materials, medical implant materials, and biological materials.
Many important elements of modern materials science have resulted from the space race. In particular, the understanding and engineering of metallic alloys, ceramics, and other materials were useful for the construction of space vehicles, space suits, and so forth, and the new knowledge was found valuable for various consumer and industrial applications as well. Materials science has laid the physical foundations of 21st century civilization, being integral to everything from fiber optic cables to tennis shoes, and from solar cells to sail boats. Materials science will continue to be centrally important in the quest for finding technological solutions toward sustainable development in the face of environmental degradation and the continued buildup of greenhouse gases due to the burning of carbon-based fuels.
In materials science, the researcher conducts a systematic investigation of each material, in terms of its structure, properties, processing, and performance. The research often leads to new applications of known materials and the creation of new materials with desired properties.
On a fundamental level, this field relates the properties and performance of a material to its atomic-scale structure and the different phases it can go through. The major factors that determine the structure and properties of a material are the nature of its constituent chemical elements and the way in which the material was processed into its final form. These factors, related through the laws of thermodynamics, govern the material's microstructure, and thus its properties.
An old adage in materials science says: "materials are like people; it is the defects that make them interesting". Given the limits of today's technology, that is good, because the manufacture of a perfect crystal of a material is physically impossible. Instead, materials scientists manipulate a material's defects to create materials with the desired properties. On an atomic scale, the defects in a crystal could mean that atoms of one element may be missing or replaced by atoms of other elements.
Not all materials have a regular crystalline structure. Glasses and some ceramics—unlike many natural materials— are amorphous, that is, they do not possess any long-range order in their atomic arrangements. Engineering these materials is much more difficult than engineering crystalline materials. Polymers may exhibit varying degrees of crystallinity, and studying them requires a combination of elements of chemical and statistical thermodynamics to give thermodynamic (rather than mechanical) descriptions of physical properties.
Radical advances in understanding and manipulating materials drive the creation of new products and even new industries. At the same time, stable industries employ materials scientists to make incremental improvements and troubleshoot issues with currently used materials. Industrial applications of materials science include the design of materials and their cost-benefit tradeoffs in industrial production.
The overlap between physics and materials science has lent itself naturally the development of the interface field of materials physics, which is concerned with the physical properties of materials. The approach is generally more macroscopic and applied than in condensed matter physics.
Each class of materials may involve a separate field of study.
Nanotechnology: As commonly understood, nanotechnology is the field of applied science and technology concerned with the formation, study, and control of materials having a width ranging from less than 1 nanometer (10−9 meter) to 100 nanometers. These materials are generally engineered on a molecular scale. On a more rigorous level, nanoscience involves the study of materials whose defining properties are present only at the nanoscale.
Crystallography: This is the study of the arrangement of atoms in a crystalline solid and the relationship between the crystalline structures and their physical properties. It includes the determination of defects associated with crystal structures.
Materials characterization: Information needed for understanding and defining the properties of materials is acquired through such techniques as diffraction of X-rays, electrons, or neutrons, and various forms of spectroscopy, chromatography, thermal analysis, or electron microscopy.
Metallurgy: This involves the study of metals and their alloys, including their extraction, microstructure, and processing.
Tribology: This is the study of the wear of materials due to friction and other factors.
Surface science: It involves study of the structures and interactions occurring at the interfaces of solids and gases, solids and liquids, and solids and solids.
Glass science: It involves the study of noncrystalline materials, including inorganic glasses, vitreous metals, and non-oxide glasses.
Some practitioners consider rheology a subfield of materials science, because it can cover any material that flows. Modern rheology, however, typically deals with non-Newtonian fluid dynamics, so it is often considered a subfield of continuum mechanics.
Thermodynamics, statistical mechanics, chemical kinetics, and physical chemistry: to understand phase stability and physical and chemical transformations.
Chemical bonding: to understand the bonds between atoms of the material.
Mechanics of materials: to understand the mechanical properties of materials and their structural applications.
Solid-state physics and quantum mechanics: to understand the electronic, thermal, magnetic, chemical, structural, and optical properties of materials.
Solid-state chemistry and polymer science: to understand the properties of polymers (including plastics), colloids, ceramics, and liquid crystals.
Biology: for the integration of materials into biological systems.
Continuum mechanics and statistics: for the study of fluid flows and ensemble systems.
Diffraction and wave mechanics: for the characterization of materials.
Askeland, Donald R. and Pradeep P. Phulé (2005). The Science & Engineering of Materials, 5th edition, Thomson-Engineering. ISBN 0534553966.
Eberhart, Mark (2003). Why Things Break: Understanding the World by the Way It Comes Apart. Harmony. ISBN 1400047609.
Gaskell, David R. (1995). Introduction to the Thermodynamics of Materials, 4th edition, Taylor and Francis Publishing. ISBN 1560329920.
Gordon, James Edward (1984). The New Science of Strong Materials or Why You Don't Fall Through the Floor, Reissue edition, Princeton University Press. ISBN 0691023808.
This page was last modified on 31 August 2018, at 15:08.


The Alexandra Palace ice skating rink is open all year round inside one of London's most iconic landmarks. Enjoy family ice skating, professional skating lessons, ice hockey and discos on ice every Friday and Saturday night. Book online for guaranteed entry and to save money.
Is Alexandra Palace Ice Skating Rink your business?


If you have psoriasis, you know all about the visual impact it can have on your body. Between 80 and 90% of people experience the buildup of thick, scaly patches of skin called "plaques." These potentially itchy plaques are the most common manifestation of this chronic, inflammatory skin disease, but psoriasis has also been linked to a number of chronic and systemic health issues. In this post, we'll discuss how psoriasis affects the body and what signs to look out for.
People with psoriatic arthritis are more likely to suffer from conjunctivitis, which is commonly referred to as "pink eye." Signs of conjunctivitis can include redness, itching, and overproduction of tears (watering eyes).
Uveitis is an inflammatory disease of the eye that about 7% of psoriasis sufferers struggle with. If you are dealing with Uveitis, you may experience eye pain, redness, blurring, and dark, floating spots in your field of vision.
Your healthcare provider, eye doctor, and dermatologist should all be consulted in order to plan for effective treatment. When caught in the early stages, serious complications, including loss of eyesight, can usually be avoided.
Studies have shown an increased risk of obesity in patients with psoriasis. In addition to obesity, psoriasis is also associated with high blood pressure, high cholesterol, heart disease, and diabetes.
In the journal, Archives of Dermatology, research was published indicating those with psoriasis are 39% more likely to be diagnosed with depression and 31% more likely to struggle with anxiety. According to Dr. Nicholas Crowley of U.S. Dermatology Partners Shoal Creek, "The psychosocial impact of psoriasis can have a major effect on patients' quality of life." Self-imposed social isolation due to feeling like they don't belong or that others view them differently is one reason so many people with psoriasis may struggle with emotional and mood disorders. For many people, connecting with others who struggle with psoriasis can help them to feel understood and supported and give them access to a network of resources who can help them stay safe and healthy. If you notice changes in your mood or behavior, feelings of hopelessness, increased feelings of panic, or suicidal thoughts, please reach out to a mental health professional or talk to your dermatologist about a referral.
Nonalcoholic fatty liver disease (NAFLD) is a condition where fat accumulates in the liver. Those with psoriasis may have an increased risk of NAFLD and cirrhosis of the liver.
Psoriasis can also affect your joints. Psoriatic arthritis can cause pain, swelling, and stiffness of the joints. In addition, you may also notice changes in your fingernails or toenails.
Hopefully, you're already working with a skilled dermatologist to control your psoriasis. If you notice any of the warning signs of these health conditions often linked to psoriasis, you should talk to your dermatologist and/or a general physician right away. If you aren't working with a dermatologist to develop a plan to treat and control the symptoms of psoriasis, finding one should be your first step. At U.S. Dermatology Partners, we unite a team of skilled dermatologists across the country to provide exceptional care. If you're interested in working with one of our dermatology professionals, complete our convenient appointment request form online. One of our friendly team members will be in touch soon to answer questions and schedule your appointment.


text:
Steve Harvey Fans Have Strong Feelings About His New Talk Show
Kayla Keegan
Prevention December 13, 2019
From Prevention
Steve Harvey is set to launch a new talk show on Facebook called STEVE on Watch.
The program will premiere on January 6, 2020.
NBC canceled the Family Feud star's daytime talk show Steve earlier this year after seven seasons.
After NBC bumped Steve Harvey's talk show to make way for Kelly Clarkson's daytime program this summer, the longtime TV host made it clear that he was optimistic about his future. As we know now, Steve's future includes hosting another talk show — this time, on Facebook.
On Tuesday, Facebook Watch announced that it will air STEVE on Watch beginning January 6, 2020. The first batch of episodes will run for 10 weeks, with multiple segments airing per week.
Photo credit: Ethan Miller
"Get ready for insightful perspectives, unfiltered responses, and surprising takes on the everyday issues affecting his audience," the announcement declares, adding that Steve "will interview remarkable people doing amazing things, get the real story of viral sensations, and get personal with some of the biggest stars of film, TV, and music."
"Reaching my audience anywhere and everywhere they are has always been the goal," Steve said in a statement. "Facebook Watch viewers are the most energetic, engaged community, and so are my amazing fans."
Amazing fans, indeed. Upon hearing the news, many took to Twitter to express their utter excitement. "I will be watching bossman! As you PREMIERE on my BIRTHDAY!! CONGRATULATIONS," one fan tweeted. "Yessssss, I knew it! I am so happy for you, they should have never taken it [the talk show] off," another said. "I'm so glad to hear that! ... We miss watching you Steve..." a different fan claimed.
Steve's big announcement comes days after he hosted the 2019 Miss Universe pageant. Besides that, he has spent the last few months working to launch Family Feud in South Africa and Ghana (which will reportedly premiere in 2020), spearheading a standup comedy contest, and hosting his annual Sand and Soul Festival in Cancun, Mexico.
Now that he's back to hosting his own talk show, we're sure 2020 will be another big year for Steve.
For can't-miss news, expert beauty advice, genius home solutions, delicious recipes, and lots more, sign up for the Good Housekeeping newsletter.
The Best Yoga Mats, According to Top Yoga Instructors
The Shockingly Simple Diet Change This Woman Made to Drop 54 Pounds
Losing Stubborn Belly Fat Really Comes Down to These Two Lifestyle Changes
RandyS: Nope, I predict a record number of lotto players over 90 days and then the hand out requests start right back up! Time to grow up and treat everyone the same.
Cut your dreadlocks or miss graduation, Texas high school tells teen


Will extra cash improve GP retention?
NHS England has announced a £10m fund intended to support GPs and encourage them to stay in the profession.
A local GP retention fund will get £7m to help keep GPs through local schemes promoting new ways of working.
The fund will support new GPs and those in their first five years. It will also support GPs who are considering leaving or changing their working hours and GPs on the national performers list (medical) but who are no longer practicing.
The remaining £3m will go to establishing seven intensive support sites across the country in areas that have struggled the most to retain GPs. Details on this will be announced next month, said NHS England.
The funding is the latest in a series of initiatives aimed at improving patient care through improving GPs quality of work life.


text:
Home / MOVIE REVIEW / 3 BEERS / 47 Meters Down: Uncaged (2019) Movie Review
47 Meters Down: Uncaged (2019) Movie Review
BabyRuth August 23, 2019 666 Views
By: BabyRuth (Three Beers) –
2016's 47 Meters Down was a surprise hit. The originally slated-for-VOD release was picked up at the last minute by Entertainment Studios and released in theaters in the summer of 2017. Turns out audiences were hungry for a good ol' shark thriller and the film ended up grossing somewhere between 43 and 65 million dollars (depending on the source – on a $5M budget that's impressive either way). Because every movie that is even modestly successful gets the sequel treatment, here we are with 47 Meters Down: Uncaged.
Once again directed and co-written by Johannes Roberts, the sequel shares the name and has a similar plot set-up to the first, but this time we are introduced to all new characters who will make the worst decision of their lives for our viewing pleasure. Once again, our two main characters are sisters, or rather step-sisters, Mia (Sophie Nélisse) and Sasha (Corinne Foxx – yup, Jamie's daughter). Both attend the same high school that for some reason has an Olympic-sized swimming pool in the courtyard (my high school had a stairwell we couldn't use whenever it rained because they were afraid the roof would cave in). We quickly learn Mia is considered an outcast and a loser at school when she is pushed into the pool by the mean girl clique's queen bee Catherine (Brec Bassinger— nope, not Kim's daughter). Mia is so not cool, even Sasha doesn't want to be associated with her. We never learn why no one likes Mia, she seems perfectly normal and doesn't even wear glasses or her hair in a ponytail, but that's all we need to know.
Mia and Sasha live in Mexico where Mia's dad Grant (John Corbett) leads a research team currently excavating a sunken Mayan city. The girls' parents (Nia Long picks up a quick check as Sasha's mother) arrange a bonding experience for the new sisters aboard a glass-bottom boat to view Great White sharks. But Sasha's friends Alexa (Brianne Tju) and Nicole (Sistine Rose Stallone- yup, Sylvester's daughter) have other ideas and convince Sasha and Mia to ditch the lame tourist attraction and join them to go hang out a private lagoon they found.
Two pop-song scored, tampon-commercial-esque montages of the teens having fun later, Alexa mentions that they are actually on the other side of the Mayan ruins that Mia's father's team is working on. She knows this because one of the researchers took her out for a dive through the first cave of the newly discovered ancient city. Alexa remembers the way and persuades the rest of the group to take one lap around the first chamber only. In and out, no biggie! There's even a ton of scuba gear sitting right there on a raft! Mia is hesitant because no one knows where they are and cave-diving is dangerous (what a loser, right?) but on the other hand, she's finally beginning to bond with Sasha and even making new friends, so she relents.
The four girls head beneath the surface and into the cave. They have those same full-face mask with speakers that allow for communication like in the first movie so we can hear their ADR underwater conversations. Everyone's having a great time and joking around and there are these really cool statues. But like my mom always used to say, "it's all fun and games until you knock over an ancient Mayan column that opens an entrance for a blind Great White to hunt you while you're trying to navigate through a dark and narrow underwater maze with your air supply dwindling."
It takes awhile to get going as we first have to meet our characters, who are pretty paper-thin, but hey, character development is not why we're here. Once the girls get to the remote location and into the conveniently placed scuba gear, it's on.
Once again, we the audience are placed deep down into the ocean (not sure if this time it's exactly 47 meters though) along with the characters to experience the dread and fear with them. We know that moment is coming when the fun stops and the panic starts and Roberts plays with the audience in getting there, making us a little more uncomfortable by the moment (in the way that you want for a film like this). The tight crevices the girls must swim through is enough to make anyone even slightly claustrophobic squirm. Like in the first, the race against time adds another obstacle as the ticking down percentage indicator of their air tanks is an even bigger threat than the hungry sharks.
There's a standout underwater scene set to "We've Only Just Begun" by the Carpenters, which now solidifies a Johannes Roberts trademark of water/music/horror mash-up sequences (His Strangers: Prey at Night also contained one, which is pretty much the only thing I remember about that movie).
The last act amps up the thrills to ludicrous, and often comical levels, but damn if I didn't have fun.
One of the things I liked most about 47 Meters Down was that the sharks behaved like actual sharks rather than movie monsters. Sure, if given the opportunity, they'd chomp on some tasty humans, but they weren't these vengeful and calculating villains, they were just…sharks. In Uncaged, Roberts abandons this idea and goes full-on Jaws and at times, even full-on Sharknado, which provides a few fun jump scares (and laughs). The main shark is blind, so there's a lot of sniffing out prey and banging into barriers. It's exciting, but in a cheaper way than the more realistic original.
Beer Three
The murky underwater setting often makes for some tough viewing. The darkness and bubbles, combined with quick cuts make the action hard to follow and it's often difficult to tell who is who (an easier task in the original when there were only two main characters). There's also a lot of tight-shots that make it hard to get an understanding of the layout of the already confusing maze-like setting.
Look, you know exactly what you're getting into with this one. If you aren't yet burned out on shark-themed entertainment between Shark Week and twenty-something Sharknado sequels, go for it. It's the Jaws 2 of this (what I assume will be a) franchise, not as good as the first, but a decent successor.
47 Meters Down: Uncaged (2019) Drinking Game
Take a Drink: whenever a character says how much air they have left
Take a Drink: whenever the shark appears
Take a Drink: whenever Mia yells "Dad!"
Take a Drink: whenever the characters think they're safe/saved
Take a Drink: when they're not
Take a Drink: whenever the shark tooth is shown
Take a Drink: every time Nicole does something stupid and selfish
Do a Shot: for every kill
About BabyRuth
Movieboozer is a humor website and drinking games are intended for entertainment purposes only, please drink responsibly.
@http://www.twitter.com/babyruthct